Alacrita Holdings Limited

Alacrita is life science consulting for a networked age. You can expect the caliber and capabilities of a top-ranked consulting firm, but you'll find a difference in our expertise. We've built our team carefully, hand-picking only those consultants with deep domain knowledge and senior business experience. With more than 200 successful client assignments each year, we're proving what's possible for commercial life sciences in a new era of opportunity.

Anthony Walker
Managing Partner 
Jess Hearn
Consultant 

Aptus Clinical Ltd

Aptus Clinical is a specialist UK- based oncology clinical research organisation which helps life science companies to optimise their clinical development strategies and effectively transform promising molecules into valued medicines.

What makes Aptus Clinical different is our flexibility – our clients benefit from our network of highly experienced and skilled experts from all technical disciplines, but only pay for what they need, when they need it. Our scientists have global expertise in all aspects of drug development so no challenge is too great, and being highly professional, they integrate seamlessly into a client organisation. This gives our clients all the benefits of an in-house clinical department, but at 
a significantly lower cost. In addition, our well-established relationships with some of the world’s leading experimental cancer centres, access to large patient populations and flexible arrangements to support optimal project delivery are just a few of the benefits to be gained from working with Aptus Clinical.

 

Jonathan Lewis
Business Development Director 

Arcinova

Arcinova is a Contract Research and Development Organisation (CRDO), providing the pharmaceutical industry with a comprehensive range of services.

At Arcinova, we are focused on Process, Research, Development, Scale-Up and small scale manufacturing, including bioanalysis, DMPK, regulatory and consulting services, covaering drug candidates in Development and launched to the Market.

Nathalie Huther
Business Development Manager Europe 

BioIndustry Association (BIA)

Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org

Michael McGivern
Membership and Business Development Manager 

BioPartner UK

BioPartner UK leads the UK Delegation to several partnering conferences
each year. It is a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.

BioPartner has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and
in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets. 

 

Lin Bateson
CEO 

Centre of Excellence in Infectious Diseases Research

Website:
www.ceidr.org.uk
Fiona Marston
Director 

Clinical Network Services (UK) Ltd

Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA. CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.

CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team. BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.

With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies. CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle. 

  

Paul Cronin
Director 
Russell Neal
Managing Director 

Conversis

Conversis is a leading ISO certified supplier of translation and localisation services, specialised in energy, technology, retail, marketing and medical.

Kim Shouler
Client Director 

Crystec Ltd

CrystecPharma is a crystal and particle engineering company applying proprietary modified supercritical fluid (SCF) technologies to improve the performance of medicines. Our technology enables drug molecules to be crystallised in new forms and novel particles to be manufactured in ways that greatly enhance their therapeutic performance. Crystec has an enabling platform which can be applied to small and large molecules, to optimise a range of medicine dosage forms (e.g. oral, inhaled, intranasal, subcutaneous, sublingual).

Crystec works with the global pharmaceutical and health care industry to solve drug particle formation, formulation and process challenges. We are also developing our own innovative therapies in important areas of unmet clinical need, including women’s health, urology and treating respiratory disease. Crystec’s proprietary ‘mSAS’ (modified Supercritical Anti-Solvent) drug delivery technology is enabled by a highly efficient, stable and fully scalable manufacturing process and is approved by regulatory authorities. The mSAS platform creates unique opportunities to improve medicines in ways that can transform the quality of life for many patients.

 

Paul Thorning
CEO 
Catherine Hunter
Business Development Director 

GTN Ltd

Noor Shaker